Genmab A/S Sponsored ADR $GMAB Shares Purchased by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC raised its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 164.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,164 shares of the company’s stock after buying an additional 63,484 shares during the quarter. Genmab A/S makes up approximately 0.6% of Legacy Wealth Asset Management LLC’s holdings, making the stock its 25th largest holding. Legacy Wealth Asset Management LLC’s holdings in Genmab A/S were worth $2,806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of GMAB. CIBC Private Wealth Group LLC lifted its holdings in shares of Genmab A/S by 291.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares during the period. NewEdge Advisors LLC grew its holdings in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares during the period. V Square Quantitative Management LLC acquired a new position in Genmab A/S during the first quarter worth approximately $34,000. Brown Brothers Harriman & Co. increased its position in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the last quarter. Finally, Osaic Holdings Inc. raised its stake in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $31.25 on Monday. The firm’s fifty day simple moving average is $27.31 and its 200 day simple moving average is $27.98. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S Sponsored ADR has a twelve month low of $21.00 and a twelve month high of $35.43. The firm has a market capitalization of $19.49 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 1.95 and a beta of 0.83.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. As a group, equities research analysts expect that Genmab A/S Sponsored ADR will post 1.11 earnings per share for the current fiscal year.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Royalty income lifted the outlook. Genmab’s drug-royalty revenue strengthened expectations for the business and was identified as a key reason the stock advanced. Genmab Stock Rises as Drug Royalties Lift Outlook
• Positive Sentiment: Q2 earnings exceeded expectations. Genmab reported EPS of $0.54, topping the $0.37 consensus estimate, while revenue of $1.16 billion surpassed expectations of $1.12 billion. The earnings beat reinforces the company’s profitability and operating momentum. Genmab Quarterly Earnings Results
• Positive Sentiment: Guggenheim raised its price target. The firm increased its target for GMAB from $40 to $42 and assigned a “Buy” rating, implying substantial upside from the stock’s recent trading level. Guggenheim Price Target Report
• Neutral Sentiment: Full-year revenue guidance is broadly in line with analyst expectations. Genmab guided to 2026 revenue of $4.3 billion to $4.5 billion, compared with consensus of approximately $4.4 billion. The range confirms continued growth but does not represent a major consensus reset. Genmab 2026 Q2 Results Presentation

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. New Street Research set a $43.00 price target on shares of Genmab A/S in a report on Wednesday, July 22nd. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and lifted their target price for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. Finally, Weiss Ratings raised Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.